Monash grants Corvus rights to undisclosed immuno-oncology program

Monash University (Clayton, Australia) granted Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) worldwide rights to an undisclosed immuno-oncology program, which includes a lead product candidate.

Corvus said it plans to develop candidates from the program as monotherapies and potentially in combination with its compound from its existing pipeline that target the adenosine receptor pathway. Corvus' CPI-444 is in a Phase I/Ib trial to treat solid tumors. Corvus has rights to the oral small molecule adenosine A2A receptor (ADORA2A) from Vernalis plc (LSE:VER)...